A discrete ubiquitin-mediated network regulates the strength of NOD2 signaling

Molecular and Cellular Biology

Volumn 33, Issue 1, 2013, Pages 146-158

  Tigno Aranjuez, Justine ^a   Bai, Xiaodong ^b   Abbott, Derek W ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CXCL11 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INHIBITOR OF APOPTOSIS PROTEIN 1; ITCH PROTEIN; TRANSCRIPTOME; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; AUTOPHOSPHORYLATION; CELL STRAIN HEK293; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UBIQUITINATION;

ANIMALS; GENE EXPRESSION PROFILING; HEK293 CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LEUCINE; LYSOSOMES; MACROPHAGES; MICE; MICE, INBRED C57BL; NOD2 SIGNALING ADAPTOR PROTEIN; PHOSPHORYLATION; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASE 2; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TYROSINE; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES;

EID: 84871914127     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01049-12     Document Type: Article

References (66)

1. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, Philpott DJ, Sansonetti PJ. 2003. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 278: 8869-8872.
2. Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, Fukase K, Inamura S, Kusumoto S, Hashimoto M, Foster SJ, Moran AP, Fernandez-Luna JL, Nunez G. 2003. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J. Biol. Chem. 278:5509-5512.
3. Cooney R, Baker J, Brain O, Danis B, Pichulik T, Allan P, Ferguson DJ, Campbell BJ, Jewell D, Simmons A. 2010. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat. Med. 16:90-97.
4. Homer CR, Richmond AL, Rebert NA, Achkar JP, McDonald C. 2010. ATG16L1 and NOD2 interact in an autophagy-dependent antibacterial pathway implicated in Crohn's disease pathogenesis. Gastroenterology 139:1630-1641, 1641 e1631-1632.
5. Inohara N, Koseki T, Lin J, del Peso L, Lucas PC, Chen FF, Ogura Y, Nunez G. 2000. An induced proximity model for NF-kappa B activation in the Nod1/RICK and RIP signaling pathways. J. Biol. Chem. 275:27823-27831.
6. Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nunez G, Flavell RA. 2005. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307:731-734.
7. McCarthy JV, Ni J, Dixit VM. 1998. RIP2 is a novel NF-kappaBactivating and cell death-inducing kinase. J. Biol. Chem. 273:16968-16975.
8. Pauleau AL, Murray PJ. 2003. Role of Nod2 in the response of macrophages to Toll-like receptor agonists. Mol. Cell. Biol. 23:7531-7539.
9. Travassos LH, Carneiro LA, Ramjeet M, Hussey S, Kim YG, Magalhaes JG, Yuan L, Soares F, Chea E, Le Bourhis L, Boneca IG, Allaoui A, Jones NL, Nunez G, Girardin SE, Philpott DJ. 2010. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat. Immunol. 11:55-62.
10. Bonen DK, Ogura Y, Nicolae DL, Inohara N, Saab L, Tanabe T, Chen FF, Foster SJ, Duerr RH, Brant SR, Cho JH, Nunez G. 2003. Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology 124:140-146.
11. Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S, Frenzel H, King K, Hasselmeyer A, MacPherson AJ, Bridger S, van Deventer S, Forbes A, Nikolaus S, Lennard-Jones JE, Foelsch UR, Krawczak M, Lewis C, Schreiber S, Mathew CG. 2001. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 357:1925-1928.
12. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G. 2001. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411:599-603.
13. Kanazawa N, Okafuji I, Kambe N, Nishikomori R, Nakata-Hizume M, Nagai S, Fuji A, Yuasa T, Manki A, Sakurai Y, Nakajima M, Kobayashi H, Fujiwara I, Tsutsumi H, Utani A, Nishigori C, Heike T, Nakahata T, Miyachi Y. 2005. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome. Blood 105:1195-1197.
14. Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu S, Hafner R, Chamaillard M, Zouali H, Thomas G, Hugot JP. 2001. CARD15 mutations in Blau syndrome. Nat. Genet. 29:19-20.
15. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nunez G, Cho JH. 2001. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411:603-606.
16. Okafuji I, Nishikomori R, Kanazawa N, Kambe N, Fujisawa A, Yamazaki S, Saito M, Yoshioka T, Kawai T, Sakai H, Tanizaki H, Heike T, Miyachi Y, Nakahata T. 2009. Role of the NOD2 genotype in the clinical phenotype of Blau syndrome and early-onset sarcoidosis. Arthritis Rheum. 60:242-250.
17. Rosé CD, Doyle TM, McIlvain-Simpson G, Coffman JE, Rosenbaum JT, Davey MP, Martin TM. 2005. Blau syndrome mutation of CARD15/ NOD2 in sporadic early onset granulomatous arthritis. J. Rheumatol. 32: 373-375.
18. Daley D, Lemire M, Akhabir L, Chan-Yeung M, He JQ, McDonald T, Sandford A, Stefanowicz D, Tripp B, Zamar D, Bosse Y, Ferretti V, Montpetit A, Tessier MC, Becker A, Kozyrskyj AL, Beilby J, McCaskie PA, Musk B, Warrington N, James A, Laprise C, Palmer LJ, Pare PD, Hudson TJ. 2009. Analyses of associations with asthma in four asthma population samples from Canada and Australia. Hum. Genet. 125:445-459.
19. Duan W, Mehta AK, Magalhaes JG, Ziegler SF, Dong C, Philpott DJ, Croft M. 2010. Innate signals from Nod2 block respiratory tolerance and program T(H)2-driven allergic inflammation. J. Allergy Clin. Immunol. 126:1284-1293 e1210.
20. Kabesch M, Peters W, Carr D, Leupold W, Weiland SK, von Mutius E. 2003. Association between polymorphisms in caspase recruitment domain containing protein 15 and allergy in two German populations. J. Allergy Clin. Immunol. 111:813-817.
21. Magalhaes JG, Fritz JH, Le Bourhis L, Sellge G, Travassos LH, Selvanantham T, Girardin SE, Gommerman JL, Philpott DJ. 2008. Nod2- dependent Th2 polarization of antigen-specific immunity. J. Immunol. 181:7925-7935.
22. Magalhaes JG, Rubino SJ, Travassos LH, Le Bourhis L, Duan W, Sellge G, Geddes K, Reardon C, Lechmann M, Carneiro LA, Selvanantham T, Fritz JH, Taylor BC, Artis D, Mak TW, Comeau MR, Croft M, Girardin SE, Philpott DJ. 2011. Nucleotide oligomerization domain-containing proteins instruct T cell helper type 2 immunity through stromal activation. Proc. Natl. Acad. Sci. U. S. A. 108:14896-14901.
23. Weidinger S, Klopp N, Rummler L, Wagenpfeil S, Baurecht HJ, Gauger A, Darsow U, Jakob T, Novak N, Schafer T, Heinrich J, Behrendt H, Wichmann HE, Ring J, Illig T. 2005. Association of CARD15 polymorphisms with atopy-related traits in a population-based cohort of Caucasian adults. Clin. Exp. Allergy 35:866-872.
24. Tigno-Aranjuez JT, Abbott DW. 2012. Ubiquitination and phosphorylation in the regulation of NOD2 signaling and NOD2-mediated disease. Biochim. Biophys. Acta 1823:2022-2028.
25. Tigno-Aranjuez JT, Asara JM, Abbott DW. 2010. Inhibition of RIP2's tyrosine kinase activity limits NOD2-driven cytokine responses. Genes Dev. 24:2666-2677.
26. Bertrand MJ, Doiron K, Labbe K, Korneluk RG, Barker PA, Saleh M. 2009. Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. Immunity 30:789-801.
27. Bertrand MJ, Lippens S, Staes A, Gilbert B, Roelandt R, De Medts J, Gevaert K, Declercq W, Vandenabeele P. 2011. cIAP1/2 are direct E3 ligases conjugating diverse types of ubiquitin chains to receptor interacting proteins kinases 1 to 4 (RIP1-4). PLoS One 6:e22356. doi:10.1371/ journal.pone.0022356.
28. Damgaard RB, Nachbur U, Yabal M, Wong WW, Fiil BK, Kastirr M, Rieser E, Rickard JA, Bankovacki A, Peschel C, Ruland J, Bekker-Jensen S, Mailand N, Kaufmann T, Strasser A, Walczak H, Silke J, Jost PJ, Gyrd-Hansen M. 2012. The ubiquitin ligase XIAP recruits LUBAC for NOD2signaling in inflammation and innate immunity. Mol. Cell 46:746-758.
29. Krieg A, Correa RG, Garrison JB, Le Negrate G, Welsh K, Huang Z, Knoefel WT, Reed JC. 2009. XIAP mediates NOD signaling via interaction with RIP2. Proc. Natl. Acad. Sci. U. S. A. 106:14524-14529.
30. Hasegawa M, Fujimoto Y, Lucas PC, Nakano H, Fukase K, Nunez G, Inohara N. 2008. A critical role of RICK/RIP2 polyubiquitination in Nodinduced NF-kappaB activation. EMBO J. 27:373-383.
31. Tao M, Scacheri PC, Marinis JM, Harhaj EW, Matesic LE, Abbott DW. 2009. ITCH K63-ubiquitinates the NOD2 binding protein, RIP2, to influence inflammatory signaling pathways. Curr. Biol. 19:1255-1263.
32. Kenneth NS, Younger JM, Hughes ED, Marcotte D, Barker PA, Saunders TL, Duckett CS. 2012. An inactivating caspase 11 passenger mutation originating from the 129 murine strain in mice targeted for c-IAP1. Biochem. J. 443:355-359.
33. Cheung HH, Plenchette S, Kern CJ, Mahoney DJ, Korneluk RG. 2008. The RING domain of cIAP1 mediates the degradation of RING-bearing inhibitor of apoptosis proteins by distinct pathways. Mol. Biol. Cell 19: 2729-2740.
34. Moulin M, Anderton H, Voss AK, Thomas T, Wong WW, Bankovacki A, Feltham R, Chau D, Cook WD, Silke J, Vaux DL. 2012. IAPs limit activation of RIP kinases by TNF receptor 1 during development. EMBOJ. 31:1679-1691.
35. Marinis JM, Homer CR, McDonald C, Abbott DW. 2011. A novel motif in the Crohn's disease susceptibility protein, NOD2, allows TRAF4 to down-regulate innate immune responses. J. Biol. Chem. 286:1938-1950.
36. Trapnell C, Pachter L, Salzberg SL. 2009. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25:1105-1111.
37. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ, Pachter L. 2010. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat. Biotechnol. 28:511-515.
38. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Stat. Methodol. 59:289-300.
39. Sekine K, Takubo K, Kikuchi R, Nishimoto M, Kitagawa M, Abe F, Nishikawa K, Tsuruo T, Naito M. 2008. Small molecules destabilize cIAP1 by activating auto-ubiquitylation. J. Biol. Chem. 283:8961-8968.
40. An MM, Fan KX, Zhang JD, Li HJ, Song SC, Liu BG, Gao PH, Zhou Q, Jiang YY. 2005. Lymphtoxin beta receptor-Ig ameliorates TNBS-induced colitis via blocking LIGHT/HVEM signaling. Pharmacol. Res. 52:234-244.
41. Mackay F, Browning JL, Lawton P, Shah SA, Comiskey M, Bhan AK, Mizoguchi E, Terhorst C, Simpson SJ. 1998. Both the lymphotoxin and tumor necrosis factor pathways are involved in experimental murine models of colitis. Gastroenterology 115:1464-1475.
42. Spahn TW, Maaser C, Eckmann L, Heidemann J, Lugering A, Newberry R, Domschke W, Herbst H, Kucharzik T. 2004. The lymphotoxin-beta receptor is critical for control of murine Citrobacter rodentium-induced colitis. Gastroenterology 127:1463-1473.
43. Wang Y, Koroleva EP, Kruglov AA, Kuprash DV, Nedospasov SA, FU YX, Tumanov AV. 2010. Lymphotoxin beta receptor signaling in intestinal epithelial cells orchestrates innate immune responses against mucosal bacterial infection. Immunity 32:403-413.
44. Barreau F, Meinzer U, Chareyre F, Berrebi D, Niwa-Kawakita M, Dussaillant M, Foligne B, Ollendorff V, Heyman M, Bonacorsi S, Lesuffleur T, Sterkers G, Giovannini M, Hugot JP. 2007. CARD15/ NOD2 is required for Peyer's patches homeostasis in mice. PloS One 2:e523. doi:doi:10.1371/journal.pone.0000523.
45. Komander D, Rape M. 2012. The ubiquitin code. Annu. Rev. Biochem. 81:203-229.
46. Hicke L, Dunn R. 2003. Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annu. Rev. Cell Dev. Biol. 19: 141-172.
47. Bergink S, Jentsch S. 2009. Principles of ubiquitin and SUMO modifications in DNA repair. Nature 458:461-467.
48. Bhoj VG, Chen ZJ. 2009. Ubiquitylation in innate and adaptive immunity. Nature 458:430-437.
49. Lauwers E, Jacob C, Andre B. 2009. K63-linked ubiquitin chains as a specific signal for protein sorting into the multivesicular body pathway. J. Cell Biol. 185:493-502.
50. Tofaris GK, Kim HT, Hourez R, Jung JW, Kim KP, Goldberg AL. 2011. Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal- lysosomal pathway. Proc. Natl. Acad. Sci. U. S. A. 108:17004-17009.
51. Varghese B, Barriere H, Carbone CJ, Banerjee A, Swaminathan G, Plotnikov A, Xu P, Peng J, Goffin V, Lukacs GL, Fuchs SY. 2008. Polyubiquitination of prolactin receptor stimulates its internalization, postinternalization sorting, and degradation via the lysosomal pathway. Mol. Cell. Biol. 28:5275-5287.
52. Chastagner P, Israel A, Brou C. 2006. Itch/AIP4 mediates Deltex degradation through the formation of K29-linked polyubiquitin chains. EMBO Rep. 7:1147-1153.
53. Salah Z, Melino G, Aqeilan RI. 2011. Negative regulation of the Hippo pathway by E3 ubiquitin ligase ITCH is sufficient to promote tumorigenicity. Cancer Res. 71:2010-2020.
54. Wei W, Li M, Wang J, Nie F, Li L. 2012. The E3 ubiquitin ligase ITCH negatively regulates canonical Wnt signaling by targeting Dishevelled protein. Mol. Cell. Biol. 32:3903-3912.
55. Kim HC, Huibregtse JM. 2009. Polyubiquitination by HECT E3s and the determinants of chain type specificity. Mol. Cell. Biol. 29:3307-3318.
56. Scialpi F, Malatesta M, Peschiaroli A, Rossi M, Melino G, Bernassola F. 2008. Itch self-polyubiquitylation occurs through lysine-63 linkages. Biochem. Pharmacol. 76:1515-1521.
57. Angers A, Ramjaun AR, McPherson PS. 2004. The HECT domain ligase itch ubiquitinates endophilin and localizes to the trans-Golgi network and endosomal system. J. Biol. Chem. 279:11471-11479.
58. Lohr NJ, Molleston JP, Strauss KA, Torres-Martinez W, Sherman EA, Squires RH, Rider NL, Chikwava KR, Cummings OW, Morton DH, Puffenberger EG. 2010. Human ITCH E3 ubiquitin ligase deficiency causes syndromic multisystem autoimmune disease. Am. J. Hum. Genet. 86:447-453.
59. Perry WL, Hustad CM, Swing DA, O'Sullivan TN, Jenkins NA, Copeland NG. 1998. The itchy locus encodes a novel ubiquitin protein ligase that is disrupted in a18H mice. Nat. Genet. 18:143-146.
60. Abbott DW, Tigno-Aranjuez JT. 8 March 2011. Compositions and methods for treating inflammatory disorders. U.S. patent PCT WO 2011/ 112588 A2.
61. Bielig H, Velder J, Saiai A, Menning M, Meemboor S, Kalka-Moll W, Kronke M, Schmalz HG, Kufer TA. 2010. Anti-inflammatory arenechromium complexes acting as specific inhibitors of NOD2 signalling. ChemMedChem 5:2065-2071.
62. Casillas LN, Chakravorty SJ, Charnley AK, Eidam P, Haile PA, Hughes TV, Jeong JU, Kang J, Lakdawala SA, Leister LK, Marquis RW, Miller NA, Price DJ, Sehon CL, Wang GZ, Zhang D. 26 March 2011. Indazolylpyrimidines as kinase inhibitors. U.S. patent PCT/US2011/030103.
63. Desai B, Haile P, Casillas L, Gough P, Bertin J, Votta B. 2012. Use of novel small molecule inhibitors to investigate the role of endogenous RIP2 kinase activity in modulating NOD2/RIP2-dependent cytokine signaling. J. Immunol. 188(Meet Abstr Suppl):172.4.
64. Magnuson G, Khan P, Yuan H, Brown B, Divlianska DB, Stonich D, Peddibhotla M, Su Y, Dad S, Sergienko E, Chung TDY, Roth GP, Wimer C, Diaz P, Correa RG, Reed JC. 2010. High throughput screening assays for NOD1 inhibitors-probe 1. Probe Reports from the NIH Molecular Libraries Program (Internet), Bethesda, MD.
65. Magnuson G, Khan P, Yuan H, Brown B, Divlianska DB, Stonich D, Peddibhotla M, Su Y, Dad S, Sergienko E, Chung TDY, Roth GP, Wimer C, Diaz P, Correa RG, Reed JC. 2010. High throughput screening assays for NOD1 inhibitors-probe 2. Probe Reports from the NIH Molecular Libraries Program (Internet), Bethesda, MD.
66. Zhao Y, Song JH, Ajami AM, Reinecker H-C. 2012. A new Rip2 kinase inhibitor for the treatment of intestinal inflammation. J. Immunol. 188(Meet Abstr Suppl):169.5.